| Objective:As a non-receptor tyrosine kinase, Syk is found expressed not only in all hematopoietic cells, but also in mammary epithelial cells, airway epithelial cells, nasal fibroblasts, vessel endothelial cells, neuron-like cells, liver cells, melanocytes and pancreatic epithelial cells which are non-hematopoietic cells. At present, the potential inhibiting effect of Syk has been discovered in several cancer research, such as breast cancer, gastric cancer, pancreatic cancer, and so on. It has been shown that the expression of Syk gradually reduces in normal breast tissue, benign lesions, low grade malignant breast tumor, invasive breast cancer, and lacks in invasive breast cancer; No expression of Syk gene has been detected in gastric carcinoma with the method of RT-PCR; Chen Mingxia, who uses RT-PCR method to study pancreatic cancer, get a similar result. Vascular endothelial growth factor-c(VEGF-C), which is found having the effect of lymphangiogenesis, is also named lymphangiogenesis factor. It has its specific receptor VEGFR-3, and they can promote lymphangiogenesis and metastasis of malignant tumors. Lung cancer, which has the highest incidence and mortality rates all over China and even the world, still has a gradually increasing trend in recent years. Non-small cell lung cancer accounts for about80%of all the lung cancer, having a difficult early diagnosis. About70%of the patients with non-small cell cancer have lost the opportunity of surgery when confirmed. Despite of widely carrying out of research of lung cancer methylation, reports in expression of Syk and regulation induced by methylation are in deficiency. The method of immunohistochemistry was used to detect the expression of Syk and VEGF-C in the non-small cell lung cancer tissue, paracancerous tissue and normal lung tissue. Meanwhile, we attempted to evaluate the relationship between the expression level of Syk and clinicopathological factors, and also evaluate the correlationship between the expression level of Syk and VEGF-C.Materials and Methods:To evaluate the expression of Syk and VEGF-C we used70surgically resected materials of non-small cell lung cancer, paracancerous lung and normal lung, while immunohistochemical evaluation were performed. And we used statistical analysis to evaluate the relationship between the expression level of Syk and clinicopathological factors, and the correlationship between the expression level of Syk and VEGF-C.Results:the positive expression rate of Syk in non-small cell lung cancer, paracancerous lung and normal lung was5.7%,95.7%,100%, there were statistically significant differences between the expression levels of Syk of normal, paracancerous and cancerous tissues (P<0.05). There were no statistically significant differences between the expression levels of Syk of normal, paracancerous tissues (P>0.05). Evaluations based on clinicopathological factors apart from histopathological differentiation, showed no statistically significant differences of Syk expression (P>0.05). The positive expression rate of VEGF-C in non-small cell lung cancer, paracancerous lung and normal lung was57.1%,10.0%,7.1%, there were statistically significant differences between the expression levels of VEGF-C of normal, paracancerous and cancerous tissues (P<0.05). There were no statistically significant differences between the expression levels of VEGF-C of normal, paracancerous tissues (P>0.05). The expression of Syk and VEGF-C has a negative correlationship(r=-1.000, P=0.000).Conclusions:the expression of Syk in non-small cell cancer significantly reduced, while the expression of VEGF-C significantly increased, they have a negative correlationship and may both have some certain effect on the occurance and development of NSCLC. Whether Syk has any influence on VEGF-C/VEGFR-3pathway or it could be used for diagnosis and treatment of lung cancer still needs more further study. |
